Bromocriptine alone or associated with L-dopa plus benserazide in Parkinson's disease.
AUTOR(ES)
Caraceni, T A
RESUMO
Twenty-six patients affected by Parkinson's disease were treated with a 2-Br-alpha-ergocriptine (CB 154): 14 cases were given CB 154 alone, and 12 were given CB 154 along with L-dopa plus benserazide (Madopar). Both CB 154 and combined therapy (CB 154+Madopar) induced a significant improvement in total disability score, tremor, rigidity, akinesia, self-sufficiency, and some motor performance tests (dynamic tests). No significant difference was found between results obtained with CB 154 therapy and with Madopar treatment, while the improvement induced by combined therapy (CB 154+Madopar) was significantly higher than that obtained by Madopar alone. The averse reactions caused by CB 154 alone or associated with Madopar are similar to those observed during other dopaminergic treatment. CB 154 alone or combined with Madopar appears to be a useful advance in the management of Parkinson's disease.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=492936Documentos Relacionados
- Influence of dystonia on the response to long-term L-dopa therapy in Parkinson's disease
- An analysis of six patients with Parkinson's disease who have been unresponsive to L-dopa therapy
- Grafting fibroblasts genetically modified to produce L-dopa in a rat model of Parkinson disease.
- Quantitative study of the effect of L-dopa and phenoxybenzamine on the rigidity of Parkinson's disease
- Plasma concentrations of L-dopa and 3-methoxydopa and improvement in clinical ratings and motor performance in patients with Parkinsonism treated with L-dopa alone or in combination with amantadine.
